IPOs & Offerings

Vogenx Prospectus Details Proposed 6,250,000-Share Initial Public Offering

Vogenx’s prospectus describes a proposed initial public offering of common stock at $13.00 per share, with delivery expected on August 13, 2026.

By Carter Hayes · August 13, 2026

Key takeaways

Vogenx is offering 6,250,000 shares of common stock at an initial public offering price of $13.00 per share.
The prospectus lists $81,250,000 as the total initial public offering price for the base offering.
The underwriters are offering the shares on a firm-commitment basis and have an option to purchase up to 937,500 additional shares.
Vogenx states that its common stock has been approved for listing on the Nasdaq Capital Market under the symbol VOGX.

Prospectus sets out proposed offering terms

Vogenx filed a prospectus for an initial public offering of 6,250,000 shares of common stock. The stated initial public offering price is $13.00 per share, and the prospectus shows a total offering price of $81,250,000 for those shares.

The document states that the underwriters expect to deliver the shares against payment in New York on August 13, 2026. That date is an expected delivery date in the prospectus and does not confirm that the offering has closed.

Jones is identified as the sole book-running manager. The prospectus says the underwriters are offering the shares on a firm-commitment basis.

Additional-share option and listing status

Vogenx granted the underwriters a 45-day option to purchase up to 937,500 additional common shares at the initial public offering price, less underwriting discounts and commissions.

Before the offering, Vogenx says there had been no public market for its common stock. Its common stock has been approved for listing on the Nasdaq Capital Market under the symbol VOGX.

The company identifies itself as an emerging growth company and a smaller reporting company, and says it elected to use certain reduced public-company reporting requirements.

Company describes development plans and funding needs

Vogenx describes itself as a clinical-stage biopharmaceutical company developing therapies for diseases associated with metabolic dysfunction. Its lead investigational product candidate, mizagliflozin, is in development for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing’s Syndrome.

The company says it has started study startup activities for a Phase 2b study in post-bariatric hypoglycemia and expects to begin screening patients in 2026. It plans to initiate a Phase 2 proof-of-concept trial in gastroparesis in 2027 and, subject to additional funding, anticipates submitting an investigational new drug application to the FDA in 2027 for GIP-dependent Cushing’s Syndrome.

Vogenx says it has incurred significant losses since inception, expects losses for the foreseeable future, and will need substantial additional funding in addition to any net proceeds from the offering.